Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2649 - Clinicians identify high need to increase their genomic literacy to applied cancer genomics


09 Oct 2016


Poster display


Janessa Laskin


Annals of Oncology (2016) 27 (6): 474-482. 10.1093/annonc/mdw387


J. Laskin1, D. Ha2, T. Chan3, A. Fok4, K.A. Gelmon1, A. Charters2, R. Yoshizawa2, S. Struve2, C. Ho1, D. Renouf1, H. Lim1, C. Simmons1, S. Taylor5, A. Tinker1, J. McGhie6, S. Jones4, M. Marra4, P. Chow-White2

Author affiliations

  • 1 Medical Oncology, British Columbia Cancer Agency, V5Z 4E6 - Vancouver/CA
  • 2 School Of Communications, Simon Fraser, Vancouver/CA
  • 3 Medical Oncology, British Columbia Cancer Agency, Vancouver/CA
  • 4 Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver/CA
  • 5 Medical Oncology, BC Cancer Agency, Kelowna/CA
  • 6 Medical Oncology, British Columbia Cancer Agency-Vancouver Island Centre, Victoria/CA


Abstract 2649


This study is the first survey of the genomic literacy of medical oncologists as co-investigators on a trial using medical genomic “big data”. The Personalized Onco-Genomics Program (POG) conducts whole genome DNA and RNA sequencing and in-depth bioinformatic analyses on patients with metastatic cancers to identify somatic variants and gene expression changes that may be targetable cancer “drivers”. Aberrant pathways are matched to drug databases and this data is reported to the clinician for each individual patient.


We conducted a survey of medical oncologists based at the six tertiary care cancer hospitals of the BC Cancer Agency (n = 31, 52.5% response rate) who enroll patients into POG. We measured oncologists' level of genomic knowledge and their experience and attitudes about genomic science and technologies.


We found a low to moderate level of genomic literacy amongst the oncologists as 48% reported having little knowledge about newer genetic/genomic technologies. Clinicians outside of the Vancouver area (the major urban centre) reported having less knowledge about new genetics technologies compared to those located in the Vancouver area (26.7% vs 73.3%, P 


The data suggests a high need to increase genomic literacy amongst oncologists beginning in medical school and with ongoing educational tools. Although these oncologists had variable experiences with POG directly informing treatment decisions; there was overall agreement that genomics and big data will play an increasingly important role in cancer care decision-making.

Clinical trial identification

Not applicable

Legal entity responsible for the study

BC Cancer Agency


BC Cancer Foundation


J. Laskin: Academic talk honoraria: AZ, Roche. Research grants to institution from: BI, Lilly and Roche. C. Ho: Honoraria AZ, Bayer, BMS, BI, Pfizer, Lilly, Roche. Research grants BI, Genzyme. Travel grant BI. D. Renouf: Honoraria from Celgene. H. Lim: Honoraria/Consulting/Research Funding: Eli Lilly, Leo, Bayer, Ipsen, Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings